Single-Dose Gene-Replacement Therapy for Spinal Muscular Atrophy
Open accessThe DOI matches its Crossref record; 25 of the 26 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Spinal muscular atrophy type 1 (SMA1) is a progressive, monogenic motor neuron disease with an onset during infancy that results in failure to achieve motor milestones and in death or the need for mechanical ventilation by 2 years of age. We studied functional replacement of the mutated gene encoding survival motor neuron 1 (SMN1) in this disease. METHODS: vg per kilogram). The primary outcome was safety. The secondary outcome was the time until death or the need for permanent ventilatory assistance. In exploratory analyses, we compared scores on the CHOP INTEND (Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders) scale of motor function (ranging from 0 to 64, with higher scores indicating better function) in the two cohorts and motor milestones in the high-dose cohort with scores in studies of the natural history of the disease (historical cohorts). RESULTS: As of the data cutoff on August 7, 2017, all 15 patients were alive and event-free at 20 months of age, as compared with a rate of survival of 8% in a historical cohort. In the high-dose cohort, a rapid increase from baseline in the score on the CHOP INTEND scale followed gene delivery, with an increase of 9.8 points at 1 month and 15.4 points at 3 months, as compared with a decline in this score in a historical cohort. Of the 12 patients who had received the high dose, 11 sat unassisted, 9 rolled over, 11 fed orally and could speak, and 2 walked independently. Elevated serum aminotransferase levels occurred in 4 patients and were attenuated by prednisolone. CONCLUSIONS: In patients with SMA1, a single intravenous infusion of adeno-associated viral vector containing DNA coding for SMN resulted in longer survival, superior achievement of motor milestones, and better motor function than in historical cohorts. Further studies are necessary to confirm the safety and efficacy of this gene therapy. (Funded by AveXis and others; ClinicalTrials.gov number, NCT02122952 .).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Notably, the FDA has approved AAV for gene replacement therapy in spinal muscular atrophy and congenital blindness, and clinical trials are in progress 58 .”
From The promise and challenge of therapeutic genome editing (2020) · cites this paper as [58]
In the citing paper
“preclinical and clinical studies have demonstrated dose-dependent inflammation, which can reduce efficacy and lead to dose-limiting toxicity (2–8)”
From Engineering adeno-associated viral vectors to evade innate immune and inflammatory responses (2021) · cites this paper as [4]
In the citing paper
“Although neuroimaging is typically more expensive than EEG and studies are limited by issues of replication, sometimes that is related to head motion that occurred during the scan which can erode signal 61”
From Autism spectrum disorder (2020) · cites this paper as [61]
In the citing paper
“Especially considering the ability of the recombinant AAV genome to persist as an episome in post-mitotic cells, such as neurons, which ensures long-term expression even after a single administration [130-132].”
From Circumventing the packaging limit of AAV-mediated gene replacement therapy for neurological disorders (2022) · cites this paper as [132]
In the citing paper
“With AAV9’s inherent ability to target motor neurons, AAV9-based Zolgensma® for the treatment of SMA has been established as the first FDA-approved drug for systemic gene therapy in CNS diseases [171].”
From Designing and optimizing AAV-mediated gene therapy for neurodegenerative diseases: from bench to bedside (2024) · cites this paper as [171]
12 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
1 retracted
Foust, K. D., Wang, X., McGovern, V. L., Braun, L., Bevan, A. K., Haidet, A. M., Le, T. T., Morales, P. R., Rich, M. M., Burghes, A. H. M., et al. (2010) · Nature Biotechnology · doi:10.1038/nbt.1610 · Cited by 688
Self-citationRetractedDeaths: preliminary data for 2003.
Hoyert, D. L., Kung, H.-C., & Smith, B. L. (2005) · PubMed · Cited by 1,649
Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes
Foust, K. D., Nurre, E., Montgomery, C. L., Hernandez, A., Chan, C. M., & Kaspar, B. K. (2009) · Nature Biotechnology · doi:10.1038/nbt.1515 · Cited by 1,456
Self-citationBayley Scales of Infant and Toddler Development, Third Edition
Bayley, N. (2012) · PsycTESTS Dataset · doi:10.1037/t14978-000 · Cited by 1,175
National Vital Statistics Reports NCHS.pdf
Hoyert, D. (2012) · Medical Entomology and Zoology · Cited by 982
Consensus Statement for Standard of Care in Spinal Muscular Atrophy
Wang, C. H., Finkel, R. S., Bertini, E. S., Schroth, M., Simonds, A., Wong, B., Aloysius, A., Morrison, L., Main, M., Crawford, T. O., et al. (2007) · Journal of Child Neurology · doi:10.1177/0883073807305788 · Cited by 961 · cited 4×
“Viral upper respiratory tract infection 0 0 3 3 (25) 3 3 (20)”
InfluentialAntisense correction of SMN2 splicing in the CNS rescues necrosis in a type III SMA mouse model
Hua, Y., Sahashi, K., Hung, G., Rigo, F., Passini, M. A., Bennett, C. F., & Krainer, A. R. (2010) · Genes & Development · doi:10.1101/gad.1941310 · Cited by 664
Sugarman, E. A., Nagan, N., Zhu, H., Akmaev, V. R., Zhou, Z., Rohlfs, E. M., Flynn, K., Hendrickson, B. C., Scholl, T., Sirko-Osadsa, D. A., et al. (2012) · European Journal of Human Genetics · doi:10.1038/ejhg.2011.134 · Cited by 661
Passini, M. A., Bu, J., Richards, A. M., Kinnecom, C., Sardi, S. P., Stanek, L. M., Hua, Y., Rigo, F., Matson, J., Hung, G., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3001777 · Cited by 547
de Onis, M., Onyango, A. W., Van den Broeck, J., Chumlea, W. C., & Martorell, R. (2004) · Food and Nutrition Bulletin · doi:10.1177/15648265040251s105 · Cited by 529
Research works printed but not linked: 1
- Hoyert DL, 2012, Natl Vital Stat Rep, 61, 1
Cited by
Items 501–600 of 1,005
Judson, M. C., Shyng, C., Simon, J. M., Davis, C. R., Punt, A. M., Salmon, M. T., Miller, N. W., Ritola, K., Elgersma, Y., Amaral, D. G., et al. (2021) · JCI Insight · doi:10.1172/jci.insight.144712 · Cited by 50
“AAV-based gene transfer can also be relatively safe and effective, as evidenced by recent FDA approval for the treatment of CNS disorders including spinal muscular atrophy and inherited retinal disease (23, 24).”
Pane, M., Donati, M. A., Cutrona, C., Sanctis, R. D., Pirinu, M., Coratti, G., Ricci, M., Palermo, C., Berti, B., Leone, D., et al. (2022) · European Journal of Pediatrics · doi:10.1007/s00431-022-04470-3 · Cited by 51
“One of these approaches is based on gene replacement (Onasemnogene Abeparvovec) with clinical trials targeting young type 1 infants [2].”
BackgroundGene therapy for monogenic disorders: challenges, strategies, and perspectives
Zhang, Y., & Wu, Z. (2023) · Journal of genetics and genomics/Journal of Genetics and Genomics · doi:10.1016/j.jgg.2023.08.001 · Cited by 46
Tiziano, F. D., Lomastro, R., Abiusi, E., Pasanisi, M. B., Pietro, L. D., Fiori, S., Baranello, G., Angelini, C. I., Sorarú, G., Gaiani, A., et al. (2018) · Journal of Medical Genetics · doi:10.1136/jmedgenet-2018-105482 · Cited by 42
Leyton-Jaimes, M. F., Kahn, J., & Israelson, A. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1904665116 · Cited by 42
“However, this can be controlled with steroid medication treatment (67).”
BackgroundMining Disaggregase Sequence Space to Safely Counter TDP-43, FUS, and α-Synuclein Proteotoxicity
Tariq, A., Lin, J., Jackrel, M. E., Hesketh, C. D., Carman, P. J., Mack, K. L., Weitzman, R., Gambogi, C. W., Murillo, O. A. H., Sweeny, E. A., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.07.069 · Cited by 44
“Food and Drug Administration (FDA) approved for congenital blindness and spinal muscular atrophy (Apte, 2018; Mendell et al., 2017).”
BackgroundMallack, E. J., Turk, B. R., Yan, H., & Eichler, F. (2019) · Current Treatment Options in Neurology · doi:10.1007/s11940-019-0605-y · Cited by 45
Pre-natal manifestation of systemic developmental abnormalities in spinal muscular atrophy
Motyl, A. A. L., Faller, K. M. E., Groen, E. J. N., Kline, R., Eaton, S. L., Ledahawsky, L. M., Chaytow, H., Lamont, D. J., Wishart, T. M., Huang, Y.-T., et al. (2020) · Human Molecular Genetics · doi:10.1093/hmg/ddaa146 · Cited by 49
“However, despite the success of both Spinraza® and Zolgensma® in improving outcomes in SMA patients, their efficacy is highly variable from one patient to another, and they modify disease course rather than providing a cure (10,15,16).”
BackgroundTang, M., & Monani, U. R. (2021) · Neuroscience Insights · doi:10.1177/26331055211011507 · Cited by 50
Gene therapy for Fabry disease: Progress, challenges, and outlooks on gene-editing
Domm, J. M., Wootton, S. K., Medin, J. A., & West, M. L. (2021) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2021.07.006 · Cited by 48
Mitochondrial Dysfunction in Spinal Muscular Atrophy
Zilio, E., Piano, V., & Wirth, B. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231810878 · Cited by 48
Physical positioning markedly enhances brain transduction after intrathecal AAV9 infusion
Castle, M. J., Cheng, Y., Asokan, A., & Tuszynski, M. H. (2018) · Science Advances · doi:10.1126/sciadv.aau9859 · Cited by 41
The Pathophysiology of Tau and Stress Granules in Disease
Cruz, A. L., Verma, M., & Wolozin, B. L. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-981-32-9358-8_26 · Cited by 46
Natural history of Type 1 spinal muscular atrophy: a retrospective, global, multicenter study
Cancés, C., Владимирович, В. Д., Comi, G. P., Masson, R., Mazurkiewicz-Bełdzińska, M., Saito, K., Zanoteli, E., Dodman, A., El-Khairi, M., Gorni, K., et al. (2022) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-022-02455-x · Cited by 43
Bossuyt, J., Herrewegen, Y. V. D., Nestor, L., Buckinx, A., de Bundel, D., & Smolders, I. (2023) · Glia · doi:10.1002/glia.24390 · Cited by 38
Evolving Therapeutic Options for the Treatment of Duchenne Muscular Dystrophy
D'Ambrosio, E. S., & Mendell, J. R. (2023) · Neurotherapeutics · doi:10.1007/s13311-023-01423-y · Cited by 49
“One particular example of modification relatively easily achieved is the adaptation of self-complementary AAV (scAAV) to deliver CRISPR sgRNAs for gene editing [75, 76]. scAAV is a well-established platform for clinical systemic gene delivery with proven efficacy [77].”
BackgroundSelf-citationGenetic therapies for inherited neuromuscular disorders
Scoto, M., Finkel, R. S., Mercuri, E. M., & Muntoni, F. (2018) · The Lancet Child & Adolescent Health · doi:10.1016/s2352-4642(18)30140-8 · Cited by 45
Lessons learned from lung and liver in-vivo gene therapy: implications for the future
van Haasteren, J., Hyde, S. C., & Gill, D. R. (2018) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2018.1506761 · Cited by 47
“were administrated intravenously and were well tolerated in a phase 1 [93], now progressing into a phase 3, clinical trial (ClinicalTrials.”
MethodChen, T., & Chen, J. (2019) · eLife · doi:10.7554/elife.50848 · Cited by 43
Adeno-Associated Virus-Based Gene Therapy for Lifelong Correction of Genetic Disease
Brommel, C. M., Cooney, A. L., & Sinn, P. L. (2020) · Human Gene Therapy · doi:10.1089/hum.2020.138 · Cited by 45
Ando, S., Suzuki, S., Okubo, S., Ohuchi, K., Takahashi, K., Nakamura, S., Shimazawa, M., Fuji, K., & Hara, H. (2020) · Scientific Reports · doi:10.1038/s41598-020-74346-9 · Cited by 44
The Burden of Spinal Muscular Atrophy on Informal Caregivers
Aranda-Reneo, I., Peña-Longobardo, L. M., Oliva, J., Litzkendorf, S., Durand‐Zaleski, I., Tizzano, E. F., & López‐Bastida, J. (2020) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph17238989 · Cited by 48
“Other recently approved approaches include intravenous gene therapy based on self-complementary adeno-associated virus with SMN1 [53] and a splicing modifier oral compound [54].”
Gushchina, L. V., Frair, E. C., Rohan, N., Bradley, A., Simmons, T. R., Chavan, H. D., Chou, H.-J., Eggers, M., Waldrop, M. A., Wein, N., et al. (2021) · Human Gene Therapy · doi:10.1089/hum.2020.286 · Cited by 43
Revisiting the role of mitochondria in spinal muscular atrophy
James, R., Chaytow, H., Ledahawsky, L. M., & Gillingwater, T. H. (2021) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-021-03819-5 · Cited by 50
Costa‐Roger, M., Blasco-Pérez, L., Cuscó, I., & Tizzano, E. F. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22169029 · Cited by 46
“The remainder approved SMA treatment OA, consists of a gene replacement therapy that restores the expression of normal SMN1 using a viral vector (AAV9) expressing SMN1 [78].”
BackgroundVeldhoen, E. S., Wijngaarde, C. A., Hulzebos, E. H. J., Asperen, R. M. W., Wadman, R. I., van Eijk, R. P. A., Asselman, F., Stam, M., Otto, L. A. M., Cuppen, I., et al. (2022) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-022-02227-7 · Cited by 49
“The absence of respiratory function measures as a primary outcome in the pivotal clinical trials of recently introduced genetic therapies for SMA is at least partially explained by the scarcity of reference data [4, 5].”
BackgroundGene therapy for primary mitochondrial diseases: experimental advances and clinical challenges
Falabella, M., Minczuk, M. A., Hanna, M. G., Viscomi, C. F., & Pitceathly, R. D. S. (2022) · Nature Reviews Neurology · doi:10.1038/s41582-022-00715-9 · Cited by 48
Current and future treatment approaches for Barth syndrome
Thompson, R., Jefferies, J. L., Wang, S., Pu, W. T., Takemoto, C. M., Hornby, B., Heyman, A., Chin, M. T., & Vernon, H. J. (2021) · Journal of Inherited Metabolic Disease · doi:10.1002/jimd.12453 · Cited by 41
He, D., Xu, Y. C., Liu, M., & Cui, L. (2023) · Aging and Disease · doi:10.14336/ad.2023.0519 · Cited by 44
“…such as antisense oligonucleotides (ASOs) and RNA interference (RNAi), are used to silence genes with toxic GoF mutations; gene editing involves correcting genetic mutations using engineered nucleases like CRISPR– Cas9; gene replacement aims to deliver functional copies of LoF mutant genes [171].”
BackgroundFocused ultrasound gene delivery for the treatment of neurological disorders
Kofoed, R. H., & Aubert, I. (2024) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2023.12.006 · Cited by 46
Firdaus, Z., & Li, X. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25042320 · Cited by 51
“In neurodegenerative diseases, spinal muscular atrophy (SMA) was the first to be cured with the exogenous introduction of SMN1 gene to children under two years of age [352].”
BackgroundXie, Q., Chen, X., Ma, H., Zhu, Y., Ma, Y., Jalinous, L., Cox, G. F., Weaver, F., Yang, J., Kennedy, Z., et al. (2024) · EMBO Molecular Medicine · doi:10.1038/s44321-024-00037-x · Cited by 44
“Three widely approved drugs, nusinersen, risdiplam, and onasemno-gene abeparvovec, have rapidly changed the SMA therapy landscape in recent years (Baranello et al, 2021; Darras et al, 2021; Finkel et al, 2017; Mendell et al, 2017; Mercuri et al, 2018).”
InfluentialEnhancing pediatric access to cell and gene therapies
Mackall, C. L., Bollard, C. M., Goodman, N., Carr, C., Gardner, R., Rouce, R. H., Sotillo, E., Stoner, R., Urnov, F. D., Wayne, A. S., et al. (2024) · Nature Medicine · doi:10.1038/s41591-024-03035-1 · Cited by 44
“Onasemnogene abeparvovec-xioi (Zolgensma), a gene replacement therapy for spinal muscular atrophy, prevents loss of function in presymptomatic infants and improves overall survival 5,6 .”
Current developments of gene therapy in human diseases
Liu, F., Li, R., Zhu, Z., Yang, Y., & Lu, F. (2024) · MedComm · doi:10.1002/mco2.645 · Cited by 48
Simpson, E. M., Korecki, A. J., Fornés, O., McGill, T. J., Vargas, J. L. C., Agostinone, J., Farkas, R. A., Hickmott, J. W., Lam, S. L., Mathelier, A., et al. (2018) · Human Gene Therapy · doi:10.1089/hum.2018.118 · Cited by 43
“23 rAAV9 was chosen primarily due to its ability to cross the blood–brain barrier and minimal capsid-based cellular specificity, 24 allowing any observed restriction of expression to reside primarily with the promoter.”
Stam, M., Wadman, R. I., Wijngaarde, C. A., Bartels, B., Asselman, F., Otto, L. A. M., Goedee, H. S., Habets, L. E., de Groot, J. F., Schoenmakers, M. A. G. C., et al. (2018) · BMJ Open · doi:10.1136/bmjopen-2017-019932 · Cited by 43
Giles, A. R., Govindasamy, L., Somanathan, S., & Wilson, J. M. (2018) · Journal of Virology · doi:10.1128/jvi.01011-18 · Cited by 40
“the number of patients eligible to receive a potentially life-saving therapy (3, 18, 19).”
BackgroundDevelopment of a Multiplex Real-Time PCR Assay for the Newborn Screening of SCID, SMA, and XLA
Gutiérrez-Mateo, C., Timonen, A., Vaahtera, K., Jaakkola, M., HOUGAARD, D. M., Bybjerg‐Grauholm, J., Bækvad‐Hansen, M., Adamsen, D., Filippov, G., Dallaire, S., et al. (2019) · International Journal of Neonatal Screening · doi:10.3390/ijns5040039 · Cited by 45
“More recently, in May 2019, Zolgensma®, an adeno-associated, virus vector-based gene therapy, received FDA approval as the first gene therapy for pediatric patients with SMA [3,4].”
BackgroundPagliarini, V., Guerra, M., Rosa, V. D., Compagnucci, C., & Sette, C. (2019) · Journal of Neurochemistry · doi:10.1111/jnc.14935 · Cited by 46
“The second one involves the transduction of motor neurons with self-complementary adeno-associated virus 9 (scAAV9) expressing exogenous SMN1 cDNA (Zolgensma) (Mendell et al., 2017).”
BackgroundTrajectory of change in the swallowing status in spinal muscular atrophy type I
Choi, Y., Suh, D. I., Chae, J., & Shin, H. (2019) · International Journal of Pediatric Otorhinolaryngology · doi:10.1016/j.ijporl.2019.109818 · Cited by 42
Newborn Screening for Spinal Muscular Atrophy in China Using DNA Mass Spectrometry
Lin, Y., Lin, C., Yin, X., Zhu, L., Yang, J., Shen, Y., Yang, C., Chen, X., Hu, H., Ma, Q., et al. (2019) · Frontiers in Genetics · doi:10.3389/fgene.2019.01255 · Cited by 40
Iqubal, A., Iqubal, M. K., Khan, A. G., Ali, J., Baboota, S., & Haque, S. E. (2020) · Current Gene Therapy · doi:10.2174/1566523220999200716111502 · Cited by 44
Newborn Screening for Spinal Muscular Atrophy: Ontario Testing and Follow-up Recommendations
McMillan, H. J., Kernohan, K. D., Yeh, E., Amburgey, K., Boyd, J. R., Campbell, C., Dowling, J. J., Gonorazky, H. D., Marcadier, J., Tarnopolsky, M. A., et al. (2020) · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · doi:10.1017/cjn.2020.229 · Cited by 46
“Therapies have emerged for the treatment of SMA.”
BackgroundInfluentialBallon, D., Rosenberg, J. B., Fung, E. K., Nikolopoulou, A., Kothari, P. J., De, B. P., He, B., Chen, A., Heier, L., Sondhi, D., et al. (2020) · Human Gene Therapy · doi:10.1089/hum.2020.116 · Cited by 42
Strategies to Uplift Novel Mendelian Gene Discovery for Improved Clinical Outcomes
Seaby, E. G., Rehm, H. L., & O’Donnell‐Luria, A. (2021) · Frontiers in Genetics · doi:10.3389/fgene.2021.674295 · Cited by 46
“, 2009; Pierce and Bennett, 2015) and the FDAapproved one-time intravenous administration of SMN cDNA to treat spinal muscular atrophy type 1 (MIM: 253300) (Mendell et al., 2017; Beck et al., 2020).”
BackgroundYom-Tov, N., Guy, R., & Offen, D. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114535 · Cited by 42
Ilyinskii, P. O., Michaud, A. M., Rizzo, G. L., Roy, C. J., Leung, S. S., Elkins, S. L., Capela, T., Chowdhury, A., Li, L., Chandler, R. J., et al. (2021) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2021.06.015 · Cited by 39
“This exact approach has been recently proven to dramatically change the outcomes of otherwise uniformly fatal neurodegenerative conditions, such as spinal muscular atrophy (SMA) type 1.(37) Moreover, it is likely that any patient treated as an infant will require additional therapeutic interventions during their lifet…”
BackgroundComplement Activation by Adeno-Associated Virus-Neutralizing Antibody Complexes
West, C., Federspiel, J. D., Rogers, K., Khatri, A., Rao-Dayton, S., Ocana, M. F., Lim, S., D'Antona, A. M., Casinghino, S., & Somanathan, S. (2023) · Human Gene Therapy · doi:10.1089/hum.2023.018 · Cited by 39
Treating neonatal spinal muscular atrophy: A 21st century success story?
Tizzano, E. F. (2019) · Early Human Development · doi:10.1016/j.earlhumdev.2019.104851 · Cited by 46
Lipid-based nanoparticles and RNA as innovative neuro-therapeutics
Tsakiri, M., Zivko, C., Demetzos, C., & Mahairaki, V. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.900610 · Cited by 41
“, 2016) or adenoassociated viruses (Wuh-Liang et al., 2012; Keiser et al., 2016; Mendell et al., 2017; Wang et al., 2018).”
Pane, M., Coratti, G., Sansone, V., Messina, S., Catteruccia, M., Bruno, C., Sframeli, M., Albamonte, E., Pedemonte, M., Brolatti, N., et al. (2023) · European Journal of Neurology · doi:10.1111/ene.15768 · Cited by 42
Enhancing gene transfer to renal tubules and podocytes by context-dependent selection of AAV capsids
Furusho, T., Das, R., Hakui, H., Sairavi, A., Adachi, K., Galbraith-Liss, M. S., Rajagopal, P., Horikawa, M., Luo, S., Li, L., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-54475-9 · Cited by 48
Massaro, G., Hughes, M. P., Whaler, S. M., Wallom, K.-L., Priestman, D. A., Platt, F. M., Waddington, S. N., & Rahim, A. A. (2020) · Human Molecular Genetics · doi:10.1093/hmg/ddz317 · Cited by 39
“Because of its ability to cross the blood-brain barrier following systemic administration (21), AAV9 has been widely used for gene delivery to the central nervous system in several preclinical studies (28) as well as in recent clinical trials for other LSDs (NCT02716246 and NCT03315182) and spinal muscular atrophy (NC…”
MethodHensel, N., Brickwedde, H., Tsaknakis, K., Grages, A., Braunschweig, L., Lüders, K. A., Lorenz, H. M., Lippross, S., Walter, L. M., Tavassol, F., et al. (2020) · Human Molecular Genetics · doi:10.1093/hmg/ddaa145 · Cited by 40
Johnson, T. B., White, K. A., Brudvig, J. J., Cain, J. T., Langin, L. M., Pratt, M. A., Booth, C. D., Timm, D. J., Davis, S. S., Meyerink, B. L., et al. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.09.033 · Cited by 39
Self-citationCappella, M., Pradat, P.-F., Querin, G., & Biferi, M. G. (2020) · Journal of Neuromuscular Diseases · doi:10.3233/jnd-200531 · Cited by 39
“These positive results obtained using ASOs for the treatment of SMA open perspectives for the application of similar approaches in ALS patients [56].”
BackgroundMethodInfluentialBlasco‐Pérez, L., Paramonov, I., Leno-Colorado, J., Bernal, S., Alías, L., Fuentes‐Prior, P., Cuscó, I., & Tizzano, E. F. (2021) · Human Mutation · doi:10.1002/humu.24200 · Cited by 44
“…in the last years of nusinersen/Spinraza, an antisense‐tailored therapy (Finkel et al., 2017), AVXS101/Zolgensma, an adeno‐associated viral‐based gene therapy (Mendell et al., 2017), as well as the recent approval of the first oral drug to treat SMA, risdiplam/Evrysdi (http:// www.fda.gov).”
BackgroundOral and Swallowing Abilities Tool (OrSAT) for Type 1 SMA Patients: Development of a New Module
Berti, B., Fanelli, L., Sanctis, R. D., Onesimo, R., Palermo, C., Leone, D., Carnicella, S., Norcia, G., Forcina, N., Coratti, G., et al. (2021) · Journal of Neuromuscular Diseases · doi:10.3233/jnd-200614 · Cited by 41
“Only in the gene replacement trial the request to report the ability to swallow thin liquids was used [8].”
Gougeon, M.-L., Poirier-Beaudouin, B., Ausseil, J., Zérah, M., Artaud, C., Heard, J.-M., Deiva, K., & Tardieu, M. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.655478 · Cited by 38
“Early works in the field demonstrated that AAV-mediated gene therapies elicit a strong host immune response (12–14), resulting in safety concerns for the patient, decreased transgene expression, and decreased longevity of transgene expression (12, 13, 15, 16).”
BackgroundGene Therapy Potential for Genetic Disorders of Surfactant Dysfunction
Cooney, A. L., Wambach, J., Sinn, P. L., & McCray, P. B. (2022) · Frontiers in Genome Editing · doi:10.3389/fgeed.2021.785829 · Cited by 52
“, 2008), Zolgensma (Mendell et al., 2017), and promising studies for Duchenne muscular dystrophy (Duan, 2018).”
BackgroundAdenoviral vectors for cardiovascular gene therapy applications: a clinical and industry perspective
Schwartze, J. T., Havenga, M. J. E., Bakker, W. A. M., Bradshaw, A. C., & Nicklin, S. A. (2022) · Journal of Molecular Medicine · doi:10.1007/s00109-022-02208-0 · Cited by 46
Cost-Effectiveness of Newborn Screening for Spinal Muscular Atrophy in The Netherlands
Velikanova, R., van der Schans, S., Bischof, M., van Olden, R. W., Postma, M. J., & Boersma, C. (2022) · Value in Health · doi:10.1016/j.jval.2022.06.010 · Cited by 45
“Compared with patients in ENDEAR/SHINE, patients in the START trial were younger at start of treatment, and fewer patients required ventilatory support.(9,43,49) Detailed information on the clinical trials is presented in Appendix Table 1 in Supplemental Materials found at https://doi.”
ResultApproaches to gene modulation therapy for ALS
Meijboom, K. E., & Brown, R. H. (2022) · Neurotherapeutics · doi:10.1007/s13311-022-01285-w · Cited by 38
Ponomarev, A. S., Chulpanova, D. S., Yanygina, L. M., Solovyeva, V. V., & Rizvanov, A. A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241813743 · Cited by 46
“Preclinical studies established raised SMN expression not only in neurons but in tissues outside CNS with a major increase in mice lifespan after 250 days [55].”
BackgroundAAV9-mediated delivery of miR-23a reduces disease severity in Smn2B/−SMA model mice
Kaifer, K. A., Villalón, E., O’Brien, B. S., Sison, S. L., Smith, C. E., Simon, M. E., Marquez, J., O’Day, S., Hopkins, A. E., Neff, R., et al. (2019) · Human Molecular Genetics · doi:10.1093/hmg/ddz142 · Cited by 39
Cost effectiveness of nusinersen for patients with infantile-onset spinal muscular atrophy in US
Thokala, P., Stevenson, M., Kumar, V., Ren, S., Ellis, A. G., & Chapman, R. H. (2020) · Cost Effectiveness and Resource Allocation · doi:10.1186/s12962-020-00234-8 · Cited by 40
Zizzi, C. E., Luebbe, E. A., Mongiovi, P. C., Hunter, M., Dilek, N., Garland, C., Ciafaloni, E., Zaidman, C. M., Kissel, J. T., McDermott, M., et al. (2021) · Muscle & Nerve · doi:10.1002/mus.27223 · Cited by 38
“expected disease progression in SMA can be modified through therapeutic intervention.(3,4) As these therapies and additional therapies are being investigated in older SMA age groups, it is worthwhile to under-”
BackgroundSelf-citationNewbornscreening SMA – From Pilot Project to Nationwide Screening in Germany
Müller‐Felber, W., Blaschek, A., Schwartz, O., Gläser, D., Nennstiel, U., Brockow, I., Wirth, B., Burggraf, S., Röschinger, W., Becker, M., et al. (2022) · Journal of Neuromuscular Diseases · doi:10.3233/jnd-221577 · Cited by 47
Between hope and reality: treatment of genetic diseases through nucleic acid-based drugs
Baylot, V., Le, T. K., Taïeb, D., Rocchi, P., & Colleaux, L. (2024) · Communications Biology · doi:10.1038/s42003-024-06121-9 · Cited by 48
“The SMA gene-therapy phase 1 trial named START (NCT02122952) results exceeded all expectations as all 15 SMA infants were alive and free of permanent ventilation, compared with a survival rate of 8% in a historical cohort 43 .”
Novel challenges in spinal muscular atrophy – How to screen and whom to treat?
Saffari, A., Kölker, S., Hoffmann, G. F., Weiler, M., & Ziegler, A. (2018) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.689 · Cited by 40
The Application of Adeno-Associated Viral Vector Gene Therapy to the Treatment of Fragile X Syndrome
Hampson, D. R., Hooper, A. W. M., & Niibori, Y. (2019) · Brain Sciences · doi:10.3390/brainsci9020032 · Cited by 40
“In the highly successful AAV trial of spinal muscular atrophy type I, the pediatric subjects were injected intravenously with a high dose of an AAV9 therapeutic vector [66].”
MethodSaladini, M., Nizzardo, M., Govoni, A., Taiana, M. M., Bresolin, N., Comi, G. P., & Corti, S. P. (2019) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.14874 · Cited by 38
On-Target CRISPR/Cas9 Activity Can Cause Undesigned Large Deletion in Mouse Zygotes
Korablev, A. N., Lukyanchikova, V., Serova, I. A., & Баттулин, Н. Р. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21103604 · Cited by 40
“Furthermore, numerous molecular biology strategies were described to significantly reduce off-target genome activities: alternative editing enzymes, such as dimeric fusions with FokI [26,27], CpfI [28,29], small Cas9 orthologs [30], CasX [31], and modified spCas9 enzymes [32,33]; improved delivery strategies, such as…”
BackgroundZiegler, A., Wilichowski, E., Schara, U., Hahn, A., Müller‐Felber, W., Johannsen, J., von der Hagen, M., von Moers, A., Stoltenburg, C., Saffari, A., et al. (2020) · Der Nervenarzt · doi:10.1007/s00115-020-00919-8 · Cited by 40
Nance, J. (2020) · CONTINUUM Lifelong Learning in Neurology · doi:10.1212/con.0000000000000918 · Cited by 45
Gene and Cell-Based Therapies for Parkinson's Disease: Where Are We?
Buttery, P. C., & Barker, R. A. (2020) · Neurotherapeutics · doi:10.1007/s13311-020-00940-4 · Cited by 44
Treatment preference among patients with spinal muscular atrophy (SMA): a discrete choice experiment
Monnette, A. M., Chen, E., Hong, D., Bazzano, A. N., Dixon, S., Arnold, W. D., & Shi, L. (2021) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-020-01667-3 · Cited by 38
Self-citationGene-Targeting Therapeutics for Neurological Disease: Lessons Learned from Spinal Muscular Atrophy
Ravi, B., Chan-Cortés, M. H., & Sumner, C. J. (2021) · Annual Review of Medicine · doi:10.1146/annurev-med-070119-115459 · Cited by 39
Spinal Muscular Atrophy: Diagnosis, Incidence, and Newborn Screening in Japan
Kimizu, T., Ida, S., Okamoto, K., Awano, H., Niba, E. T. E., Wijaya, Y. O. S., Okazaki, S., Shimomura, H., Lee, T., Tominaga, K., et al. (2021) · International Journal of Neonatal Screening · doi:10.3390/ijns7030045 · Cited by 40
“According to early reports of clinical trials, nusinersen and onasemnogene abeparvovec helped patients to reach milestones in their motor function development and increased their likelihood of survival [10,11].”
BackgroundPardridge, W. M. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114234 · Cited by 44
Prime Editing: An All-Rounder for Genome Editing
Lu, C., Kuang, J., Shao, T., Xie, S., Li, M., Zhu, L., & Zhu, L. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23179862 · Cited by 48
“The AAV vector has clinically advantageous features, such as replication incompetence, low immunogenicity, different serotypes, and tissue specificity [41,42].”
BackgroundIn Situ Detection of Adeno-associated Viral Vector Genomes with SABER-FISH
Wang, S. K., Lapan, S. W., Hong, C. M., Krause, T. B., & Cepko, C. L. (2020) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2020.10.003 · Cited by 36
“In recent years, use of AAV vectors in patients has grown tremendously, highlighted by the advent of gene therapy treatments for Leber’s congenital amaurosis and spinal muscular atrophy.(8,9) The translational potential of AAV vectors has now led to more than 200 phase I, II, and III clinical trials (https://clinicalt…”
BackgroundGenetic Advancements in Infantile Epileptic Spasms Syndrome and Opportunities for Precision Medicine
Snyder, H., Jain, P., RamachandranNair, R., Jones, K., & Whitney, R. (2024) · Genes · doi:10.3390/genes15030266 · Cited by 42
“Adenovirus-associated virus (AAV) gene replacement has been approved for and completely redefined clinical outcomes for spinal muscular atrophy and is being studied for genetic epilepsies such as Dravet syndrome [132,133].”
BackgroundCharcot-Marie-tooth disease type 2A: An update on pathogenesis and therapeutic perspectives
Alberti, C., Rizzo, F., Anastasia, A., Comi, G. P., Corti, S. P., & Abati, E. (2024) · Neurobiology of Disease · doi:10.1016/j.nbd.2024.106467 · Cited by 41
“Despite gene therapies being widely approved as treatments for neuromuscular diseases like SMA, there is a lack of literature regarding gene therapy studies for CMT2A.”
Kachanov, A., Kostyusheva, A. P., Brezgin, S. A., Karandashov, I. V., Ponomareva, N. I., Tikhonov, A., Lukashev, A. N., Pokrovsky, V. S., Zamyatnin, A. A., Parodi, A., et al. (2024) · Medicinal Research Reviews · doi:10.1002/med.22036 · Cited by 49
Gene therapy for hemophilia – From basic science to first approvals of “one-and-done” therapies
Herzog, R. W., Kaczmarek, R., & High, K. A. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.03.043 · Cited by 43
“12,81,82 Building on these results, the next clinical trial, initiated in 2010, utilized AAV8 capsid, which had been superior in transduction of murine liver compared with AAV2 and showed reduced prevalence of pre-existing NAbs in the human population.”
Assessment of motor unit loss in patients with spinal muscular atrophy
Sleutjes, B. T. H. M., Wijngaarde, C. A., Wadman, R. I., Otto, L. A. M., Asselman, F., Cuppen, I., van den Berg, L. H., van der Pol, W. L., & Goedee, H. S. (2020) · Clinical Neurophysiology · doi:10.1016/j.clinph.2020.01.018 · Cited by 39
Spinal muscular atrophy care in the COVID‐19 pandemic era
Veerapandiyan, A., Connolly, A. M., Finkel, R. S., Arya, K., Mathews, K. D., Smith, E. C., Castro, D., Butterfield, R. J., Parsons, J. A., Servais, L., et al. (2020) · Muscle & Nerve · doi:10.1002/mus.26903 · Cited by 39
“20 We emphasize that treatment decisions should be individualized and made cohesively between the patient, family, and healthcare provider, taking into account any geographic-or institution-specific policies and precautions for COVID-19.”
Paulk, N. (2020) · Genetic Engineering & Biotechnology News · doi:10.1089/gen.40.09.04 · Cited by 35
The respiratory impact of novel therapies for spinal muscular atrophy
Paul, G., Gushue, C. A., Kotha, K. S., & SHELL, R. D. (2020) · Pediatric Pulmonology · doi:10.1002/ppul.25135 · Cited by 38
“Fifteen patients with SMA1, homozygous SMN1 exon 7 deletions, and 2 copies of SMN2 received a single intravenous infusion of onasemnogene.(15) At the therapeutic dose, apart from achievement of motor milestones and better motor function, a remarkable event‐free survival of 100% without need for permanent ventilation a…”
ResultSelf-citationArnold, W. D., Severyn, S. A., Zhao, S., Kline, D., Linsenmayer, M., Kelly, K., Tellez, M., Bartlett, A., Heintzman, S., Reynolds, J., et al. (2021) · BMJ Neurology Open · doi:10.1136/bmjno-2021-000164 · Cited by 39
Self-citationMarcó, S., Haurigot, V., Jaén, M. L., Ribera, A., Sánchez, V., Molas, M., Garcia, M., León, X., Roca, C., Sánchez, X., et al. (2021) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2021.09.017 · Cited by 45
Spinal muscular atrophy: from rags to riches
Mercuri, E. M. (2021) · Neuromuscular Disorders · doi:10.1016/j.nmd.2021.08.009 · Cited by 42
Long Noncoding RNAs as Therapeutic Targets
Pierce, J. B., Zhou, H., Simion, V., & Feinberg, M. W. (2022) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-92034-0_9 · Cited by 41
Onasemnogene abeparvovec for the treatment of spinal muscular atrophy
Mcmillan, H., Proud, C., Farrar, M., Alexander, I., Muntoni, F., & Servais, L. (2022) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2022.2066471 · Cited by 32
“CHOP INTEND scores declined in the historic cohort [48].”
BackgroundInfluentialLee, J., Lee, H., Lee, H. G., Shin, M., Shin, M.-G., Seo, J., Lee, E. J., Park, S. A., & Park, S. (2023) · Nature Communications · doi:10.1038/s41467-023-44319-3 · Cited by 42
Słyk, Ż., Stachowiak, N., & Małecki, M. (2024) · Biomedicines · doi:10.3390/biomedicines12071523 · Cited by 44
Recent developments in gene therapy for Parkinson’s disease
Szunyogh, S., Carroll, E., & Wade‐Martins, R. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.03.030 · Cited by 45
“10 While only a small percentage of PD cases are directly attributed to a specific genetic mutation, 11 gene therapy that targets underlying disease pathways offer the potential for more widely applicable treatments.”
New Directions for SMA Therapy
Messina, S. (2018) · Journal of Clinical Medicine · doi:10.3390/jcm7090251 · Cited by 44
“The number of SMN2 copies is variable, and because each copy produces low levels of full-length, functional SMN, the number of SMN2 copies is inversely related to symptom severity and clinical subtype [5].”
BackgroundInfluentialCancer therapy with a CRISPR-assisted telomerase-activating gene expression system
Dai, W., Xu, X., Wang, D., Wu, J., & Wang, J. (2019) · Oncogene · doi:10.1038/s41388-019-0707-8 · Cited by 35
Metadata
- Authors
- Mendell, J. R., Al-Zaidy, S., Shell, R., Arnold, W. D., Rodino-Klapac, L. R., Prior, T. W., Lowes, L., Alfano, L., Berry, K., Church, K., Kissel, J. T., Nagendran, S., L’Italien, J., Sproule, D. M., Wells, C., Cardenas, J. A., Heitzer, M. D., Kaspar, A., Corcoran, S., Braun, L., Likhite, S., Miranda, C., Meyer, K., Foust, K. D., Burghes, A. H. M., & Kaspar, B. K.
- Affiliations
- Abigail Wexner Research Institute (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2017-11-02
- Volume
- 377
- Issue
- 18
- Pages
- 1713-1722
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2765253110
- Cited by
- 2,381
- References
- 26
- Citations by year
- 2026: 205 · 2025: 232 · 2024: 292 · 2023: 270 · 2022: 289 · 2021: 347 · 2020: 298 · 2019: 246 · 2018: 172 · 2017: 16
- FWCI
- 115.14
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Nationwide Children's Hospital
- AveXis
- Research Institute, Nationwide Children's Hospital
- Topics
- Health Sciences › Medicine › Genetics (clinical) › Neurogenetic and Muscular Disorders Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Health Sciences › Medicine › Genetics (clinical) › Lysosomal Storage Disorders Research
- Keywords
- spinal muscular atrophy type 1, gene replacement therapy, adeno-associated virus vectors, SMN1, motor function, motor milestones, survival, CHOP INTEND, aminotransferase elevation, prednisolone, treatment efficacy and safety
- MeSH terms
- Dependovirus, Female, Genetic Vectors, Humans, Infant, Infant, Newborn, Infusions, Intravenous, Liver Diseases, Male, Motor Skills, Respiration, Artificial, Spinal Muscular Atrophies of Childhood, Genetic Therapy, Cohort Studies, Nutritional Support, Disease-Free Survival, Survival of Motor Neuron 1 Protein, Historically Controlled Study
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.